Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. Academic Article uri icon

Overview

abstract

  • MAGE-3 is the most commonly expressed cancer testis Ag and thus represents a prime target for cancer vaccines, despite infrequent natural occurrence of MAGE-3-specific immune responses in vivo. We report in this study the successful induction of Ab, CD8(+), and CD4(+) T cells in nonsmall cell lung cancer patients vaccinated with MAGE-3 recombinant protein. Two cohorts were analyzed: one receiving MAGE-3 protein alone, and one receiving MAGE-3 protein with adjuvant AS02B. Of nine patients in the first cohort, three developed marginal Ab titers and another one had a CD8(+) T cell response to HLA-A2-restricted peptide MAGE-3 271-279. In contrast, of eight patients from the second cohort vaccinated with MAGE-3 protein and adjuvant, seven developed high-titered Abs to MAGE-3, and four had a strong concomitant CD4(+) T cell response to HLA-DP4-restricted peptide 243-258. One patient simultaneously developed CD8(+) T cells to HLA-A1-restricted peptide 168-176. The novel monitoring methodology used in this MAGE-3 study establishes that protein vaccination induces clear CD4(+) T cell responses that correlate with Ab production. This development provides the framework for further evaluating integrated immune responses in vaccine settings and for optimizing these responses for clinical benefit.

publication date

  • March 1, 2004

Research

keywords

  • Antigens, Neoplasm
  • CD4-Positive T-Lymphocytes
  • Cancer Vaccines
  • Carcinoma, Non-Small-Cell Lung
  • Lipid A
  • Lung Neoplasms
  • Neoplasm Proteins
  • Vaccines, DNA

Identity

Scopus Document Identifier

  • 10744229438

Digital Object Identifier (DOI)

  • 10.4049/jimmunol.172.5.3289

PubMed ID

  • 14978137

Additional Document Info

volume

  • 172

issue

  • 5